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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.003High-temperature requirement serine protease A1 (HTRA1) is one of four known proteases belonging to the
broadly conserved family of HTRA proteins. Although it was originally considered as representing an
important modulator of tumorigenesis, an increasing number of reports have suggested that its inﬂuence on
human diseasemay extend beyond cancer. HTRA1 has the capacity to degrade numerous extracellular matrix
proteins, and as such, its potential involvement in diseases of the musculoskeletal system has been gaining
increased attention. Musculoskeletal disease constitutes a wide variety of degenerative conditions that can
manifest themselves in different ways such as joint and back pain, as well as deﬁciencies in skeletal bone
quality, and ultimately result in signiﬁcant suffering and reduced quality of life. Convincing data now exist
to support a detrimental role for HTRA1 in the pathogenesis of joint and intervertebral disk degeneration.
However, the function of HTRA1 in other closely related musculoskeletal diseases affecting bone and muscle
remains unclear and largely unexplored. To help set the stage for future research, we discuss here some of
the recent advances in our understanding of the role played by HTRA1 in musculoskeletal pathology.
(Am J Pathol 2013, 182: 1482e1488; http://dx.doi.org/10.1016/j.ajpath.2013.02.003)Supported by Forschungskredit Zurich University, Uniscientia, and
Novartis.The high-temperature requirement serine protease (HTRA)
family constitutes a well-conserved group of proteolytic
enzymes (HTRA1, 2, 3, and 4), having key roles in protein
quality control as well as in the regulation of various
signaling pathways through the degradation of speciﬁc
substrates.1,2 Of the four known members, HTRA1 and -2
are the best characterized and are considered to play
important roles in human cancer and neurodegeneration.3,4
Despite sharing several structural similarities such as
a protease domain and a PDZ domain, HTRA2 exists solely
as an intracellular protein, whereas HTRA1 can also be
secreted by virtue of its N-terminal signal peptide. Since its
initial identiﬁcation by Zumbrunn and Trueb5 over 15 years
ago, HTRA1 has been extensively studied in terms of both
its structure and its function.6,7 HTRA1 can exist in various
oligomeric states, and in comparison to the bacterial
homolog DegP, its activity is not dependent on the PDZ
domain.7 Other notable differences between HTRA1 andstigative Pathology.
.DegP include an additional insulin-like growth factor-
binding protein (IGFBP) and Kazal-like domain in the N-
terminal region of HTRA1. However, recent evidence
suggests that although they are homologous to the prototype
proteins, neither of these domains has any known regulatory
function with respect to HTRA1 enzymatic activity.6
The availability of HTRA1 as a secreted protease has
prompted investigations into identifying its extracellular
substrates and has so far resulted mainly in the discovery of
growth factors andmatrix proteins as being the primary targets
of HTRA1-dependent proteolysis. The number of extracel-
lular matrix (ECM) proteins identiﬁed as HTRA1 substrates
has steadily been growing over the years and now includes,
among others, ﬁbronectin, type-II collagen, decorin, aggrecan,
elastin, bone sialoprotein (IBSP), and matrix Gla protein.8e12
Role of HTRA1 in Musculoskeletal DiseaseThis has encouraged further research into the potential role of
HTRA1 in human diseases in which breakdown of the ECM is
considered to be of signiﬁcant importance. Subsequently, new
evidence is emerging that implicates HTRA1 in several
musculoskeletal diseases (MSDs) affecting bone, joint, and
muscle.
The aim of this review is therefore to expand on our
current knowledge relating to the involvement of HTRA1 in
human disease. Our understanding of the role of HTRA1 in
disease is continually being challenged and requires regular
updating to afford us with the necessary information to
allow for the evaluation of HTRA1 as a potential therapeutic
target. The structural and functional properties associated
with HTRA1, and how these relate to its role in human
disease, have already been discussed elsewhere2,6,7,13 and
will not be readdressed here. We will instead focus more on
examining the evidence available to implicate HTRA1 in
MSD pathology and how we can exploit this knowledge to
help combat such debilitating disorders.
Musculoskeletal Disease
Musculoskeletal is deﬁned as relating to muscles and skel-
eton, and encompasses a wide variety of tissues, including
muscles, bones, cartilage, joints, tendons, and ligaments.
MSDs are generally considered to be, although perhaps
wrongly, an inevitable part of growing old and are seen to
be the most widespread conditions affecting the aged pop-
ulation.14 Due to their high prevalence, MSDs are seen to
represent a signiﬁcant burden, both to the affected indi-
vidual and to society as a whole.14,15 Furthermore, this
burden is likely to increase over the coming years due to
rising longevity and shifts in the population pyramid
favoring a higher proportion of senior citizens. Signiﬁcant
efforts are therefore being made to try and combat the most
debilitating of the MSDs, including conditions relating to
rheumatism, back pain, and osteoporosis, and involve basic
and applied research approaches geared toward improving
our understanding of the biological processes that govern
these diseases. To this end, an increasing number of
researchers are now focusing their attention on HTRA1 as
a possible causal agent in the pathology of several closely
related MSDs. To date, the most convincing evidence for
the involvement of HTRA1 in MSD comes from studies
involving patients with rheumatoid arthritis (RA) or osteo-
arthritis (OA), although there is now speculation that
HTRA1 may also play a role in spine disease and possibly
even osteoporosis and muscular dystrophy. Each of these
conditions and their association with HTRA1 will be dis-
cussed in turn during the course of this Mini-Review.
Rheumatic Disorders
The term rheumatic disorder covers a wide variety of
conditions, of which OA and RA are considered to have theThe American Journal of Pathology - ajp.amjpathol.orggreatest impact on public health. OA is the most prevalent
form of arthritis and is characterized by a breakdown in
articular cartilage as well as degeneration of other joint
tissues, including synovium and subchondral bone.16 Orig-
inally considered to be a noninﬂammatory disorder, OA has
since been associated with a low-level inﬂammatory
response.17 It has been speculated that inﬂammation brought
about through joint trauma may in fact be one of the main
instigators of OA.18 The supervening wave of cytokines
released during this initiation phase is important, not only in
the development of pain-related symptoms, but also in
cartilage destruction via the up-regulation of catabolic
agents such as proteolytic enzymes, the chief being the
matrix metalloproteinases (MMPs).19
Hu et al20 were the ﬁrst to demonstrate that in addition to
the known enzymes up-regulated in OA patients, HTRA1
production is also signiﬁcantly enhanced, with increases in
both HTRA1 mRNA and protein being measured in arthritic
cartilage explants. This ﬁnding was conﬁrmed almost
a decade later in a study examining soluble protein levels in
articular cartilage tissue using a comparative proteomics
analysis approach.21 Of the 814 proteins identiﬁed within
tissue samples taken from normal and OA patient groups, 59
were considered as being differentially expressed. HTRA1
represented one such protein and was shown to be up-
regulated by up to eightfold in OA cartilage as compared
to normal cartilage. This was in good agreement with the
sevenfold increase in the expression of HTRA1 mRNA
originally reported by Hu et al.20 These observations were
later corroborated by ﬁndings from similar studies using
genetic22,23 or proteomic24 approaches to assess mecha-
nisms underlying OA development. Although HTRA1 is
ﬁrmly established as being up-regulated in joint degenera-
tion, there still remained the question as to the role of
HTRA1 in arthritis pathology.
Synovial ﬁbroblasts play a key role in mediating
inﬂammation and joint destruction as observed in RA.25 In
addition to being a potent source of cytokines and chemo-
kines, synovial ﬁbroblasts also have the potential to secrete
a barrage of matrix-degrading enzymes of which the MMPs
are considered to be of primary importance in the patho-
genesis of both OA and RA.26 It has previously been
demonstrated that in addition to HTRA1 being up-regulated
in both OA and RA patients, it was also capable of inducing
MMP production by synovial ﬁbroblasts isolated from OA
and RA patients.8 Furthermore, the stimulatory effects of
HTRA1 were shown to be reliant on its proteolytic activity
and were mediated in part through the generation of ﬁbro-
nectin fragments. These ﬁndings, not only are suggestive of
HTRA1 as having a detrimental role in arthritis pathology,
but also offer a novel mechanism through which its actions
may be mediated. Certainly, ﬁbronectin fragments are
considered to be of central importance in driving the
arthritic process through their ability to stimulate MMP
secretion.27,28 Clearly, based on the diverse proteolytic
nature of HTRA1, this may be only part of the story, and its1483
Tiaden and Richardsinteraction with other proteoglycans within the joint cannot
be ruled out as a possible cause for its effects in arthritic
disease. For instance, type-II collagen is a known HTRA1
substrate, and its degradation products are up-regulated in
OA and can themselves induce ECM breakdown.29e31 More
direct evidence comes from studies investigating the ability
of HTRA1 to cleave the proteoglycan aggrecan, a major
component of the articular cartilage ECM.12 HTRA1-
digested aggrecan fragments were found to be up-
regulated in OA cartilage, being localized to chondrocytes
and areas of cartilage where proteoglycan loss was greatest.
At present, it is unclear as to whether such fragments play
any functional role in mediating cellular function, as do
ﬁbronectin fragments.
The relevance of HTRA1 to arthritic disease progression
has also been investigated in experimental models that closely
simulate the human condition. Initial evidence for its
involvement came from studies performed in mice with
collagen-induced arthritis, where levels of HTRA1 mRNA
were shown to be elevated in accordance with the appearance
of joint swelling.32 Furthermore, immunohistochemical anal-
ysis revealed that HTRA1 protein localized to hypertrophic
chondrocytes in the deep layers of degraded articular cartilage,
although it remained largely absent from cells undergoing
apoptosis. Interestingly, HTRA3, another secreted HTRA
member with high homology to HTRA1, was also found to be
overexpressed in the articular cartilage of arthritic mice,
although this was conﬁnedmainly to the superﬁcial layer.33 In
both cases, the proteolytic action of HTRA1 and HTRA3 on
various ECM proteoglycans, including decorin and biglycan,
was implicated as being a potential contributory factor to
disease progression. These observations have since been
extended to studies in mouse OA models, where increased
levels of HTRA1 were identiﬁed in articular cartilage from
diseased mice in association with both MMP13 and discoidin
domain-containing receptor 2 (Ddr2),34,35 both of which
are considered key elements in the cartilage breakdown
cascade.36,37 It was proposed that HTRA1 might mediate its
effects through removal of the protective pericellular matrix
surrounding chondrocytes, leading to exposure of cells to the
network of surrounding collagen ﬁbers and induction of
chondrocyte hypertrophy. HTRA1may therefore represent an
additional component of what may be a central molecular
pathway responsible for initiating OA cartilage degeneration.
Furthermore, it is possible that inactivation ofHTRA1 through
targeted therapy using speciﬁc chemical inhibitors or anti-
bodies may constitute an effective means by which to control
the breakdown of joint tissue and thus limit disease severity.Spinal Disk Degeneration
Acquired degenerative stenosis is by far the most common
cause of chronic back pain, arising mainly from a breakdown
in the structural integrity of lumbar intervertebral disks
(IVDs).38 IVDs are primarily designed to counteract1484compressive forces on the spine and to maintain vertebral
separation, thus allowing for unrestricted movement. IVD
degeneration is considered to be predominantly an age-
related phenomenon, resulting in loss of disk height as well
as increases in disk bulging and subsequent impingement of
nerve roots. Changes in matrix turnover and cell activity are
believed to be two of the major contributors of structural
integrity failure encountered in degenerating IVDs39 and are
closely associated with an overproduction of matrix-
degrading enzymes.40 The localization of both MMPs and
their inhibitors to cells of the nucleus pulposus and inner
ﬁbrosus compartments of the IVD would tend to suggest that
these cells are of central importance in the development and
progression of IVD disease.
With regard to the involvement of HTRA1 in IVD
degeneration, initial insights came from studies examining
genetic changes in the HTRA1 promoter region of Japanese
women with IVD degeneration, where a single nucleotide
polymorphism, rs11200638, was identiﬁed as being a risk
factor for spinal disk space narrowing.41 This interesting
observation was impetus for further studies undertaken by
our laboratory in which we assessed the role HTRA1 in IVD
degeneration in a small European patient population.10 A
detrimental role for HTRA1 in IVD degeneration was
alluded to be based on its ability to stimulate MMP and
aggrecanase production by cultured IVD cells. Furthermore,
despite our being unable to show any association of
rs11200638 with disease severity, we were able to demon-
strate that HTRA1 production was signiﬁcantly up-regulated
in degenerated IVD tissue explants and was directly corre-
lated with appearance of both C- and N-terminal ﬁbronectin
fragments. This ﬁnding is considered to be of particular
relevance based on the fact that ﬁbronectin fragments have
already been closely linked with the detrimental effects of
HTRA1 in arthritis.8 As with arthritis, ﬁbronectin fragments
are believed to have a signiﬁcant inﬂuence on disease
progression.42 Therefore, it is possible that HTRA1 medi-
ates its destructive effects in both spine and joint disease
through a common mechanism involving the generation of
reactive ﬁbronectin fragment species. Although, as already
alluded to earlier in this Mini-Review, one cannot exclude
the possibility that other proteoglycans within the ECM are
also susceptible to the actions of HTRA1. As with OA
cartilage, increases in type-II collagen degradation products
are common features of IVD degeneration43 and have the
potential to activate resident cells.44 Evidently, further
investigations are needed to better deﬁne the role of such
breakdown products in the destruction of both cartilage and
IVD tissue.Age-Related Osteoporosis
Osteoporosis is deﬁned as a systemic disease characterized
by reduced bone mass and low bone mineral density, with
a subsequent increase in bone fragility and vulnerability toajp.amjpathol.org - The American Journal of Pathology
Role of HTRA1 in Musculoskeletal Diseasefractures.45 Bone formation is reliant on the presence of
functionally active mature osteoblasts derived from
progenitor cells within the bone marrow, termed bone
marrow stromal cells (BMSCs), through a process of oste-
ogenic differentiation. The observation that BMSCs isolated
from aged osteoporotic patients have a higher propensity
toward adipogenesis than osteogenesis implies that the
structural abnormalities associated with osteoporotic bone
may be a consequence of inadequacies in bone cell differ-
entiation.46 This is further supported by data from experi-
mental models of osteoporosis.47 Clearly, therefore,
identifying factors involved in controlling BMSC lineage
commitment and subsequent bone formation may be a key
step in developing successful therapeutic strategies for the
treatment of age-related osteoporotic bone loss and
prevention of associated fractures.
The suggestion that HTRA1 may play a role in bone
formation originally came from detailed in situ hybridiza-
tion and immunohistochemical studies performed in tissues
from mice at various stages of development.32,48 HtrA1
gene expression was identiﬁed in undifferentiated mesen-
chymal cells in the vicinity of pre-cartilage condensations,
as well as in osteocytes within bone matrix. Positive staining
for HTRA1 protein was visualized in areas associated withThe American Journal of Pathology - ajp.amjpathol.orgboth endochondral ossiﬁcation and intramembranous ossi-
ﬁcation, suggestive of a central role for HTRA1 in bone
remodeling. This concept is supported by ﬁndings from our
own studies examining HTRA1 levels during fracture
healing in mice, where we identiﬁed a noticeable increase in
HTRA1 protein expression at sites of active bone formation
within both osteoblasts and hypertrophic chondrocytes.9
Similarly, enhanced HTRA1 expression has also been
observed in dentin during reparative dentin formation
induced in rats.49
Until recently, the role of HTRA1 in bone formation and
disease was generally considered to be a negative one. This
was based on the ﬁndings of Hadﬁeld et al,11 where over-
expression of HTRA1 in immortalized mouse 2T3 osteo-
blasts was associated with decreases in matrix mineralization.
However, recent ﬁndings from our own studies investigating
human BMSC (hBMSC) osteogenesis somewhat contradict
this model.9 We could show that hBMSCs induced to
undergo osteogenic differentiation were reliant on functional
HTRA1 and that when added in excess, could greatly
enhance osteoblast formation and mineralized matrix depo-
sition. Although the exact mechanisms by which HTRA1
mediated its osteoanabolic effects were not fully investigated,
strong evidence was given implicating HTRA1-dependentFigure 1 Proposed scenario for the inﬂuence
of HTRA1 on the musculoskeletal system and its
contribution to MSD. HTRA1 is regarded as having
a negative role in both IVD and joint degeneration
through its direct and indirect effects on ECM
components and MMP production, respectively.
HTRA1 is therefore strongly implicated in the
pathology of spine and joint disease alike. The
ability of HTRA1 to dictate BMSC lineage commit-
ment in favor of osteogenesis may impart to it
a positive role in the maintenance of bone quality
and development of age-related bone loss. The up-
regulation of HTRA1 in degenerating muscle, along
with its capacity to alter the activation status of
speciﬁc growth factors (GFs) involved in regulating
muscle growth, are suggestive of a role in regu-
lating muscle disease. However, it remains
unknown as to whether HTRA1 acts as a negative
or positive mediator of muscle quality.
1485
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direct contrast to its inﬂuence on hBMSC osteogenesis,
HTRA1 was also shown to act as a negative regulator of
hBMSC adipogenesis and may therefore additionally
represent a key mediator of fat marrow adiposity. If true, this
may have signiﬁcant implications in terms of the potential of
HTRA1 as a therapeutic target for treating osteoporosis,
where such imbalances in bone and fat marrow are wholly
evident. One could even contemplate a scenario where
deﬁciencies in HTRA1 activity may in fact be part of the
underlying pathology. However, it still remains to be seen
whether abnormalities in HTRA1 regulation can be linked to
osteoporosis development. Therefore, although further
studies are necessary to deﬁne its exact role in bone
pathology, the majority of evidence to date points toward
HTRA1 as having a positive inﬂuence on bone formation.Muscular Dystrophy
The degenerative muscle disease Duchenne muscular
dystrophy (DMD) affects 1 in 3500 males and is due to
a mutation in the dystrophin gene, leading to a high suscep-
tibility to skeletal muscle injury in patient sufferers.50 This
results in the degeneration of muscle ﬁbers and their subse-
quent replacement by adipose and ﬁbrous tissue. The patho-
physiological pathways governing these downstream events
are undoubtedly complex and overlapping, although some
insights into these processes have already be gleaned through
the use of microarray analysis. In one such study, HTRA1
gene expression was found to be increased by 4.4- to 5.5-fold
in DMD muscle as compared to normal control tissue.51
Although no functional analyses were performed in this
study, it was speculated that high levels of HTRA1 within
dystrophin-deﬁcient muscle may actually contribute indi-
rectly to muscle degeneration through inactivation of
IGFBP5, a well-recognized HTRA1 substrate.52 IGFBP5 is
considered to be a positive regulator of muscle regeneration
through its ability to augment insulin-like growth factor-1
(IGF-1) signaling.53 As such, down-regulation of IGFBP5
activity by HTRA1 may have negative functional conse-
quences on the potential of IGF-1 to stimulate muscle growth.
However, it is also conceivable that HTRA1 could act to
counter the effects of dystrophin deﬁciency in muscle tissue.
This notion is based on the ability of HTRA1 to inhibit the
activities of several members of the transforming growth
factor-b superfamily, including bone morphogenetic
proteins, activin, and growth differentiation factors,48 and the
suggestion that transforming growth factor-b signaling is
causally linked to defects in myogenesis and the subsequent
development of DMD.54,55 Based on previous observations
regarding the inﬂuence ofHTRA1 overmesenchymal stromal
cell differentiation,9 investigations into HTRA1’s involve-
ment in myogenic differentiation may therefore represent
a logical next step when considering how best to elucidate the
role of HTRA1 in DMD development and progression.1486Concluding Remarks
Despite increases in our understanding of the pathophysiolog-
ical processes governing the majority of the most debilitating
MSDs, new and more efﬁcacious treatment regimens are still
needed. The fact that HTRA1 has been implicated as an
important contributory factor in the pathogenesis of several
MSDs, includingRA,OA, and IVDdegeneration, suggests that
it maywell represent a novel therapeutic target for the treatment
of such diseases. However, the potential for HTRA1 to deliver
beneﬁcial effects in other closely related MSDs, such as oste-
oporosis and DMD, should give pause for thought in terms of
how treatment strategies are to be designed and implemented
(Figure1).Aspreviouslymentioned,MSDencompasses awide
variety of pathological conditions affecting numerous different
skeletal tissues. It is highly likely therefore that the effects of
HTRA1 in MSD extend beyond what has been discussed in
this Mini-Review. Certainly, the promiscuous nature of the
substrate selectivity of HTRA1 leaves open the possibility of it
being a central player in a variety of diseases involving modi-
ﬁcations of the ECM. Future consideration should therefore be
given to othermajorMSDswhere alterations inmatrix turnover
and composition are contributing factors to disease develop-
ment. We propose tendinopathy as being one such MSD,
which, as far as we are aware, has not yet been linked with
changes in HTRA1 production. However, new studies may be
warranted due to the close association between tendinopathy
and other MSDs such as OA, in which HTRA1 is considered
a key player. On the basis of the information presented in this
Mini-Review, we are in no doubt that the number of MSDs
linked to HTRA1 production and/or activity will continue to
rise, although it remains uncertain as towhetherHTRA1will be
deemed beneﬁcial or detrimental to disease pathology.References
1. Clausen T, Southan C, Ehrmann M: The HtrA family of proteases: impli-
cations for protein composition and cell fate. Mol Cell 2002, 10:443e455
2. Clausen T, Kaiser M, Huber R, Ehrmann M: HTRA proteases: regu-
lated proteolysis in protein quality control. Nat Rev Mol Cell Biol
2011, 12:152e162
3. Chien J, Campioni M, Shridhar V, Baldi A: HtrA serine proteases as
potential therapeutic targets in cancer. Curr Cancer Drug Targets 2009,
9:451e468
4. Launay S, Maubert E, Lebeurrier N, Tennstaedt A, Campioni M,
Docagne F, Gabriel C, Dauphinot L, Potier MC, Ehrmann M, Baldi A,
Vivien D: HtrA1-dependent proteolysis of TGF-beta controls both
neuronal maturation and developmental survival. Cell Death Differ
2008, 15:1408e1416
5. Zumbrunn J, Trueb B: Primary structure of a putative serine protease
speciﬁc for IGF-binding proteins. FEBS Lett 1996, 398:187e192
6. Eigenbrot C, Ultsch M, Lipari MT, Moran P, Lin SJ, Ganesan R,
Quan C, Tom J, Sandoval W, van Lookeren Campagne M,
Kirchhofer D: Structural and functional analysis of HtrA1 and its
subdomains. Structure 2012, 20:1040e1050
7. Truebestein L, Tennstaedt A, Mönig T, Krojer T, Canellas F,
Kaiser M, Clausen T, Ehrmann M: Substrate-induced remodeling of
the active site regulates human HTRA1 activity. Nat Struct Mol Biol
2011, 18:386e388ajp.amjpathol.org - The American Journal of Pathology
Role of HTRA1 in Musculoskeletal Disease8. Grau S, Richards PJ, Kerr B, Hughes C, Caterson B, Williams AS,
Junker U, Jones SA, Clausen T, Ehrmann M: The role of human HtrA1
in arthritic disease. J Biol Chem 2006, 281:6124e6129
9. Tiaden AN, Breiden M, Mirsaidi A, Weber FA, Bahrenberg G,
Glanz S, Cinelli P, Ehrmann M, Richards PJ: Human serine protease
HTRA1 positively regulates osteogenesis of human bone marrow-
derived mesenchymal stem cells and mineralization of differentiating
bone-forming cells through the modulation of extracellular matrix
protein. Stem Cells 2012, 30:2271e2282
10. Tiaden AN, Klawitter M, Lux V, Mirsaidi A, Bahrenberg G, Glanz S,
Quero L, Liebscher T, Wuertz K, Ehrmann M, Richards PJ: Detri-
mental role for human high temperature requirement serine protease a1
(HTRA1) in the pathogenesis of intervertebral disc (IVD) degenera-
tion. J Biol Chem 2012, 287:21335e21345
11. Hadﬁeld KD, Rock CF, Inkson CA, Dallas SL, Sudre L, Wallis GA,
Boot-Handford RP, Canﬁeld AE: HtrA1 inhibits mineral deposition by
osteoblasts: requirement for the protease and PDZ domains. J Biol
Chem 2008, 283:5928e5938
12. Chamberland A, Wang E, Jones AR, Collins-Racie LA, LaVallie ER,
Huang Y, Liu L, Morris EA, Flannery CR, Yang Z: Identiﬁcation of
a novel HtrA1-susceptible cleavage site in human aggrecan: evidence
for the involvement of HtrA1 in aggrecan proteolysis in vivo. J Biol
Chem 2009, 284:27352e27359
13. Zurawa-Janicka D, Skorko-Glonek J, Lipinska B: HtrA proteins as
targets in therapy of cancer and other diseases. Expert Opin Ther
Targets 2010, 14:665e679
14. Woolf AD, Pﬂeger B: Burden of major musculoskeletal conditions.
Bull World Health Organ 2003, 81:646e656
15. Brooks PM: The burden of musculoskeletal diseaseda global
perspective. Clin Rheumatol 2006, 25:778e781
16. Heinegård D, Saxne T: The role of the cartilage matrix in osteoarthritis.
Nature Rev Rheumatol 2011, 7:50e56
17. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H:
Role of proinﬂammatory cytokines in the pathophysiology of osteo-
arthritis. Nat Rev Rheumatol 2011, 7:33e42
18. Lotz M: Osteoarthritis year 2011 in review: biology. Osteoarthritis
Cartilage 2012, 20:192e196
19. Troeberg L, Nagase: Proteases involved in cartilage matrix degradation
in osteoarthritis. Biochim Biophys Acta 2012, 1824:133e145
20. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM: Human
HtrA, an evolutionarily conserved serine protease identiﬁed as
a differentially expressed gene product in osteoarthritic cartilage. J Biol
Chem 1998, 273:34406e34412
21. Wu J, Liu W, Bemis A, Wang E, Qiu Y, Morris EA, Flannery CR,
Yang Z: Comparative proteomic characterization of articular cartilage
tissue from normal donors and patients with osteoarthritis. Arthritis
Rheum 2007, 56:3675e3684
22. Swingler TE, Waters JG, Davidson RK, Pennington CJ, Puente XS,
Darrah C, Cooper A, Donell ST, Guile GR, Wang W, Clark IM:
Degradome expression proﬁling in human articular cartilage. Arthritis
Res Ther 2009, 11:R96
23. Milner JM, Patel A, Davidson RK, Swingler TE, Desilets A,
Young DA, Kelso EB, Donell ST, Cawston TE, Clark IM, Ferrell WR,
Plevin R, Lockhart JC, Leduc R, Rowan AD: Matriptase is a novel
initiator of cartilage matrix degradation in osteoarthritis. Arthritis
Rheum 2010, 62:1955e1966
24. Rosenthal AK, Gohr CM, Ninomiya J, Wakim BT: Proteomic analysis
of articular cartilage vesicles from normal and osteoarthritic cartilage.
Arthritis Rheum 2011, 63:401e411
25. Bottini N, Firestein GS: Duality of ﬁbroblast-like synoviocytes in RA:
passive responders and imprinted aggressors. Nat Rev Rheumatol 2012
Nov 13, [Epub ahead of print]
26. Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role
in arthritis. Front Biosci 2006, 11:529e543
27. Homandberg GA: Potential regulation of cartilage metabolism in
osteoarthritis by ﬁbronectin fragments. Front Biosci 1999, 4:
D713eD730The American Journal of Pathology - ajp.amjpathol.org28. Stanton H, Ung L, Fosang AJ: The 45 kDa collagen-binding fragment
of ﬁbronectin induces matrix metalloproteinase-13 synthesis by
chondrocytes and aggrecan degradation by aggrecanases. Biochem J
2002, 364:181e190
29. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR:
Damage to type II collagen in aging andosteoarthritis starts at the articular
surface, originates around chondrocytes, and extends into the cartilage
with progressive degeneration. J Clin Invest 1995, 96:2859e2869
30. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R,
Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H,
Chen J, Van Wart H, Poole AR: Enhanced cleavage of type II collagen
by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997,
99:1534e1545
31. Yasuda T, Tchetina E, Ohsawa K, Roughley PJ, Wu W, Mousa A,
Ionescu M, Pidoux I, Poole AR: Peptides of type II collagen can
induce the cleavage of type II collagen and aggrecan in articular
cartilage. Matrix Biol 2006, 25:419e429
32. Tsuchiya A, Yano M, Tocharus J, Kojima H, Fukumoto M,
Kawaichi M, Oka C: Expression of mouse HtrA1 serine protease in
normal bone and cartilage and its upregulation in joint cartilage
damaged by experimental arthritis. Bone 2005, 37:323e336
33. Tocharus J, Tsuchiya A, Kajikawa M, Ueta Y, Oka C, Kawaichi M:
Developmentally regulated expression of mouse HtrA3 and its role as
an inhibitor of TGF-beta signaling. Dev Growth Differ 2004, 46:
257e274
34. Polur I, Lee PL, Servais JM, Xu L, Li Y: Role of HTRA1, a serine
protease, in the progression of articular cartilage degeneration. Histol
Histopathol 2010, 25:599e608
35. Holt DW, Henderson ML, Stockdale CE, Farrell JT, Kooyman DL,
Bridgewater LC, Seegmiller RE: Osteoarthritis-like changes in the
heterozygous sedc mouse associated with the HtrA1-Ddr2-Mmp-13
degradative pathway: a new model of osteoarthritis. Osteoarthritis
Cartilage 2012, 20:430e439
36. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z,
Shah M, Thompson EW: Matrix metalloproteinase 13-deﬁcient mice
are resistant to osteoarthritic cartilage erosion but not chondrocyte
hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:
3723e3733
37. Xu L, Servais J, Polur I, Kim D, Lee PL, Chung K, Li Y: Attenuation
of osteoarthritis progression by reduction of discoidin domain receptor
2 in mice. Arthritis Rheum 2010, 62:2736e2744
38. Katz JN, Harris MB: Lumbar spinal stenosis. New Eng J Med 2008,
358:818e825
39. Adams MA, Roughley PJ: What is intervertebral disc degeneration,
and what causes it? Spine (Phila Pa 1976) 2006, 31:2151e2161
40. Le Maitre CL, Freemont AJ, Hoyland JA: Localization of degradative
enzymes and their inhibitors in the degenerate human intervertebral
disc. J Pathol 2004, 204:47e54
41. Urano T, Narusawa K, Kobayashi S, Shiraki M, Horie-Inoue K,
Sasaki N, Hosoi T, Ouchi Y, Nakamura T, Inoue S: Association of
HTRA1 promoter polymorphism with spinal disc degeneration in
Japanese women. J Bone Miner Metab 2010, 28:220e226
42. Anderson DG, Markova D, Adams SL, Paciﬁci M, An HS, Zhang Y:
Fibronectin splicing variants in human intervertebral disc and associa-
tion with disc degeneration. Spine (Phila Pa 1976) 2010, 35:1581e1588
43. Hollander AP, Heathﬁeld TF, Liu JJ, Pidoux I, Roughley PJ, Mort JS,
Poole AR: Enhanced denaturation of the alpha (II) chains of type-II
collagen in normal adult human intervertebral discs compared with
femoral articular cartilage. J Orthop Res 1996, 14:61e66
44. Mwale F, Wang HT, Zukor DJ, Huk OL, Petit A, Antoniou J: Effect of
a type II collagen fragment on the expression of genes of the extracellular
matrix in cells of the intervertebral disc. Open Orthop J 2008, 2:1e9
45. Rachner TD, Khosla S, Hofbauer LC: Osteoporosis: now and the
future. Lancet 2011, 377:1276e1287
46. Rodríguez JP, Garat S, Gajardo H, Pino AM, Seitz G: Abnormal
osteogenesis in osteoporotic patients is reﬂected by altered mesen-
chymal stem cells dynamics. J Cell Biochem 1999, 75:414e4231487
Tiaden and Richards47. Jilka RL, Weinstein RS, Takahashi K, Parﬁtt AM, Manolagas SC:
Linkage of decreased bone mass with impaired osteoblastogenesis in
a murine model of accelerated senescence. J Clin Invest 1996, 97:
1732e1740
48. Oka C, Tsujimoto R, Kajikawa M, Koshiba-Takeuchi K, Ina J,
Yano M, Tsuchiya A, Ueta Y, Soma A, Kanda H, Matsumoto M,
Kawaichi M: HtrA1 serine protease inhibits signaling mediated by
Tgfbeta family proteins. Development 2004, 131:1041e1053
49. Li X, Zhou M, Wang X, Li R, Han N, Zhang Q: Quantitative deter-
mination of high-temperature requirement protein A1 and its possible
associated molecules during induced reparative dentin formation. J
Endod 2012, 38:814e820
50. Nowak KJ, Davies KE: Duchenne muscular dystrophy and dystrophin:
pathogenesis and opportunities for treatment. EMBO Rep 2004, 5:
872e876
51. Bakay M, Zhao P, Chen J, Hoffman EP: A web-accessible complete
transcriptome of normal human and DMD muscle. Neuromuscul
Disord 2002, 12:S125eS141148852. Hou J, Clemmons DR, Smeekens S: Expression and characterization of
a serine protease that preferentially cleaves insulin-like growth factor
binding protein-5. J Cell Biochem 2005, 94:470e484
53. Kuemmerle JF, Zhou H: Insulin-like growth factor-binding
protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in
human intestinal smooth muscle by Ras-dependent activation of
p38 MAP kinase and Erk1/2 pathways. J Biol Chem 2002, 277:
20563e20571
54. Haidet AM, Rizo L, Handy C, Umapathi P, Eagle A, Shilling C,
Boue D, Martin PT, Sahenk Z, Mendell JR, Kaspar BK: Long-term
enhancement of skeletal muscle mass and strength by single gene
administration of myostatin inhibitors. Proc Natl Acad Sci U S A 2008,
105:4318e4322
55. Shi S, Hoogaars WM, de Gorter DJ, van Heiningen SH, Lin HY,
Hong CC, Kemaladewi DU, Aartsma-Rus A, ten Dijke P, ’t Hoen PA:
BMP antagonists enhance myogenic differentiation and ameliorate the
dystrophic phenotype in a DMD mouse model. Neurobiol Dis 2011,
41:353e360ajp.amjpathol.org - The American Journal of Pathology
